KSHV inflammatory cytokine syndrome

Summary

KSHV inflammatory cytokine syndrome (MONDO:0023528) is a disease and 2 clinical trials. Top therapeutic interventions include pacritinib and rituximab. A subtype of post-infectious syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	KSHV inflammatory cytokine syndrome
Mondo ID	MONDO:0023528
NCIT	C125711
UMLS	C4086533
MedGen	901443
GARD	0027912
Is cancer (heuristic)	no

Also known as: Kaposi-sarcoma associated Herpesvirus (KSHV) inflammatory cytokine syndrome · KICS · KSHV inflammatory cytokine syndrome

Disease family

Classification path: disease › human disease › disease by body system or component › syndromic disease › post-infectious syndrome › KSHV inflammatory cytokine syndrome

Related subtypes (2): Zika virus congenital syndrome, TORCH syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01419561	PHASE2	RECRUITING	Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
NCT06052618	PHASE2	RECRUITING	Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PACRITINIB	4	1
RITUXIMAB	4	1
CHEMBL4778465	0	1